公开(公告)号：US20220079942A1

公开(公告)日：2022-03-17

申请号：US17244171

申请日：2021-04-29

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US20170158706A1

公开(公告)日：2017-06-08

申请号：US15417191

申请日：2017-01-26

Applicant: Cancer Research Technology Limited

Inventor： Bruce D. Dorsey ,  Keith S. Learn ,  Emma L. Morris ,  Gregory R. Ott ,  Jonathan R.A. Roffey ,  Christelle N. Soudy ,  Jason C. Wagner

IPC: C07D495/04 ,  C07D495/20 ,  C07D495/14 ,  C07D519/00

CPC classification number: C07D495/04 ,  C07D495/14 ,  C07D495/20 ,  C07D519/00 ,  C07F7/0812

Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.

公开(公告)号：US11020396B2

公开(公告)日：2021-06-01

申请号：US16348073

申请日：2017-11-07

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: C07D403/14 ,  A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US09914730B2

公开(公告)日：2018-03-13

申请号：US14038915

申请日：2013-09-27

Applicant: Ignyta, Inc. ,  Cancer Research Technology Limited

Inventor： Henry J. Breslin ,  Bruce D. Dorsey ,  Benjamin J Dugan ,  Katherine M. Fowler ,  Robert L Hudkins ,  Eugen F. Mesaros ,  Nathaniel J. T. Monck ,  Emma L. Morris ,  Ikeoluwa Olowoye ,  Gregory R. Ott ,  Gregoire A. Pave ,  Jonathan R. Roffey ,  Christelle N. Soudy ,  Ming Tao ,  Craig A. Zificsak ,  Allison L. Zulli

IPC: A61K31/675 ,  C07D471/04 ,  C07D519/00 ,  C07D493/08 ,  C07D498/04 ,  C07F9/6584

CPC classification number: C07D471/04 ,  C07D493/08 ,  C07D498/04 ,  C07D519/00 ,  C07F9/6584

Abstract: The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C (“aPKC”) inhibitory activity, and may be used to treat proliferative disorders.

公开(公告)号：US20140323435A1

公开(公告)日：2014-10-30

申请号：US14285007

申请日：2014-05-22

Applicant: Cancer Research Technology Limited ,  Cephalon, Inc.

Inventor： Bruce D. Dorsey ,  Keith S. Learn ,  Emma L. Morris ,  Gregory R. Ott ,  Jonathan R.A. Roffey ,  Christelle N. Soudy ,  Jason C. Wagner

IPC: C07D495/04 ,  C07D495/20 ,  C07F7/08 ,  C07D495/14

CPC classification number: C07D495/04 ,  C07D495/14 ,  C07D495/20 ,  C07D519/00 ,  C07F7/0812

Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.

Abstract translation: 本申请提供式（I）化合物或其盐，其中R 1，R 2，R 3，R 4，R 5，R 6，A，G，M，Q和X如本文所定义。 式（I）化合物及其盐具有PKC抑制活性，可用于治疗增殖性疾病。